Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Exp Cell Res

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    August 2024
  1. XU M, Gao X, Yue L, Li J, et al
    Sensitivity of Triple Negative Breast Cancer cells to ATM-dependent Ferroptosis Induced by Sodium Selenite.
    Exp Cell Res. 2024 Aug 28:114222. doi: 10.1016/j.yexcr.2024.114222.
    PubMed     Abstract available


  2. WANG X, Li P, Zhang Z, Wang X, et al
    N6-methyladenosine modification of linc-OIP5 confers paclitaxel resistance in breast cancer through a DDX5-dependent mechanism.
    Exp Cell Res. 2024 Aug 27:114226. doi: 10.1016/j.yexcr.2024.114226.
    PubMed     Abstract available


  3. MA S, Pu C
    MiR-519e-5p regulates malignant phenotype of breast cancer cells through binding to CTPS1.
    Exp Cell Res. 2024 Aug 26:114225. doi: 10.1016/j.yexcr.2024.114225.
    PubMed     Abstract available


  4. CHOUDHURY AR, Nagesh AM, Gupta S, Chaturvedi PK, et al
    MicroRNA signature of stromal-epithelial interactions in prostate and breast cancers.
    Exp Cell Res. 2024;441:114171.
    PubMed     Abstract available


    April 2024
  5. SHOME R, Sen P, Sarkar S, Ghosh SS, et al
    Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/beta-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer.
    Exp Cell Res. 2024 Apr 5:114032. doi: 10.1016/j.yexcr.2024.114032.
    PubMed     Abstract available


    February 2024
  6. SHI X, Sun Y, Zhang Y, Wang W, et al
    Corrigendum to "MEX3A promotes development and progression of breast cancer through regulation of PIK3CA" [Exp. Cell Res. 2021 Jul 1;404(1):112580. Epub 2021 Apr 1.].
    Exp Cell Res. 2024;436:113964.
    PubMed    


  7. LI Y, Wei D, Chen Z, Chen Y, et al
    RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities.
    Exp Cell Res. 2024;435:113932.
    PubMed     Abstract available


  8. XU W, Goreczny GJ, Forsythe I, Brennan G, et al
    Hic-5 regulates extracellular matrix-associated gene expression and cytokine secretion in cancer associated fibroblasts.
    Exp Cell Res. 2024;435:113930.
    PubMed     Abstract available


    December 2023
  9. XU WH, Zhang T, Zhou Y, Mao Y, et al
    Fluvastatin prevents lung metastasis in triple-negative breast cancer by triggering autophagy via the RhoB/PI3K/mTOR pathway.
    Exp Cell Res. 2023 Dec 18:113893. doi: 10.1016/j.yexcr.2023.113893.
    PubMed     Abstract available


    November 2023
  10. MA X, Wan R, Wen Y, Liu T, et al
    Deubiquitinating enzyme OTUD4 regulates metastasis in triple-negative breast cancer by stabilizing Snail1.
    Exp Cell Res. 2023 Nov 29:113864. doi: 10.1016/j.yexcr.2023.113864.
    PubMed     Abstract available


  11. MONTEIRO M, Zhang X, Yee D
    Insulin promotes growth in breast cancer cells through the type I IGF receptor in insulin receptor deficient cells.
    Exp Cell Res. 2023 Nov 28:113862. doi: 10.1016/j.yexcr.2023.113862.
    PubMed     Abstract available


    October 2023
  12. WANG C, Zhao X, Zhao L, Wang Y, et al
    PKCzeta phosphorylates VASP to mediate chemotaxis in breast cancer cells.
    Exp Cell Res. 2023 Oct 25:113823. doi: 10.1016/j.yexcr.2023.113823.
    PubMed     Abstract available


  13. TULUHONG D, Gao H, Li X, Wang L, et al
    Squalene epoxidase promotes breast cancer progression by regulating CCNB1 protein stability.
    Exp Cell Res. 2023 Oct 13:113805. doi: 10.1016/j.yexcr.2023.113805.
    PubMed     Abstract available


  14. LIU D, Guo Y, Du Q, Zhu Y, et al
    RING induces cell cycle arrest and apoptosis in human breast cancer cells by regulating the HSF1/MT2A axis.
    Exp Cell Res. 2023 Oct 3:113795. doi: 10.1016/j.yexcr.2023.113795.
    PubMed     Abstract available


    September 2023
  15. JING L, Zhou K, Wang Z, Li Y, et al
    YTHDF1 shapes "cold" tumor and inhibits CD8(+) T cells infiltration and function in breast cancer.
    Exp Cell Res. 2023;432:113778.
    PubMed     Abstract available


    August 2023
  16. ZHOU X, Guo X, Han J, Wang M, et al
    Cytochrome b561 regulates iron metabolism by activating the Akt/mTOR pathway to promote Breast Cancer Cells proliferation.
    Exp Cell Res. 2023 Aug 25:113760. doi: 10.1016/j.yexcr.2023.113760.
    PubMed     Abstract available


  17. WANG R, Gou Y, Tang M, Wang K, et al
    A mutator-derived prognostic eRNA signature provides insight into the pathogenesis of breast cancer.
    Exp Cell Res. 2023 Aug 21:113754. doi: 10.1016/j.yexcr.2023.113754.
    PubMed     Abstract available


  18. HUANG X, Wu J, Wang Y, Xian Z, et al
    FOXQ1 inhibits breast cancer ferroptosis and progression via the circ_0000643/miR153/SLC7A11 axis.
    Exp Cell Res. 2023 Aug 15:113737. doi: 10.1016/j.yexcr.2023.113737.
    PubMed     Abstract available


    May 2023
  19. TUGRUL B, Balcan E, Oztel Z, Collu F, et al
    Prion protein-dependent regulation of p53-MDM2 crosstalk during endoplasmic reticulum stress and doxorubicin treatments might be essential for cell fate in human breast cancer cell line, MCF-7.
    Exp Cell Res. 2023;429:113656.
    PubMed     Abstract available


  20. TAN X, Li Y, Hou Z, Zhang M, et al
    Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer.
    Exp Cell Res. 2023 May 22:113647. doi: 10.1016/j.yexcr.2023.113647.
    PubMed     Abstract available


  21. TSENG LM, Lau KY, Chen JL, Chu PY, et al
    Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model.
    Exp Cell Res. 2023 May 18:113652. doi: 10.1016/j.yexcr.2023.113652.
    PubMed     Abstract available


    April 2023
  22. MAHMOUD L, Cougnoux A, Bekiari C, Araceli Ruiz de Castroviejo Teba P, et al
    Microscopy-based phenotypic monitoring of MDA-MB-231 spheroids allows the evaluation of phenotype-directed therapy.
    Exp Cell Res. 2023;425:113527.
    PubMed     Abstract available


    March 2023
  23. CAO C, Lu X, Guo X, Zhao H, et al
    Patient-derived models: Promising tools for accelerating the clinical translation of breast cancer research findings.
    Exp Cell Res. 2023;425:113538.
    PubMed     Abstract available


    February 2023
  24. LIU B, Qu X, Wang J, Xu L, et al
    LINC00365 functions as a tumor suppressor by inhibiting HIF-1alpha-mediated glucose metabolism reprogramming in breast cancer.
    Exp Cell Res. 2023 Feb 15:113514. doi: 10.1016/j.yexcr.2023.113514.
    PubMed     Abstract available


    January 2023
  25. ZHENG R, Yu Y, Lv L, Zhang Y, et al
    m(6)A reader HNRNPA2B1 destabilization of ATG4B regulates autophagic activity, proliferation and olaparib sensitivity in breast cancer.
    Exp Cell Res. 2023 Jan 21:113487. doi: 10.1016/j.yexcr.2023.113487.
    PubMed     Abstract available


    October 2022
  26. JIN Y, Cai W, Zhao C, Yang F, et al
    EMT status of circulating breast cancer cells and impact of fluidic shear stress.
    Exp Cell Res. 2022 Oct 10:113385. doi: 10.1016/j.yexcr.2022.113385.
    PubMed     Abstract available


    September 2022
  27. WU K, Zhang H, Zhou L, Chen L, et al
    Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer.
    Exp Cell Res. 2022 Sep 21:113362. doi: 10.1016/j.yexcr.2022.113362.
    PubMed     Abstract available


  28. SINHA S, Chatterjee S, Paul S, Das B, et al
    Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
    Exp Cell Res. 2022 Sep 5:113338. doi: 10.1016/j.yexcr.2022.113338.
    PubMed     Abstract available


    August 2022
  29. FOURIE C, du Plessis M, Mills J, Engelbrecht AM, et al
    The effect of HIF-1alpha inhibition in breast cancer cells prior to doxorubicin treatment under conditions of normoxia and hypoxia.
    Exp Cell Res. 2022;419:113334.
    PubMed     Abstract available


  30. KANNO Y, Saito N, Saito R, Kosuge T, et al
    Differential DNA-binding and cofactor recruitment are possible determinants of the synthetic steroid YK11-dependent gene expression by androgen receptor in breast cancer MDA-MB 453 cells.
    Exp Cell Res. 2022;419:113333.
    PubMed     Abstract available


    June 2022
  31. GAO H, Li H, Wang J, Xu C, et al
    Polyamine synthesis enzyme AMD1 is closely related to the tumorigenesis and prognosis of human breast cancer.
    Exp Cell Res. 2022 Jun 4:113235. doi: 10.1016/j.yexcr.2022.113235.
    PubMed     Abstract available


  32. XIAO H, Long J, Chen X, Tan MD, et al
    NUPR1 promotes the proliferation and migration of breast cancer cells by activating TFE3 transcription to induce autophagy.
    Exp Cell Res. 2022 Jun 2:113234. doi: 10.1016/j.yexcr.2022.113234.
    PubMed     Abstract available


    May 2022
  33. UDDIN MB, Roy KR, Hill RA, Roy SC, et al
    p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection.
    Exp Cell Res. 2022 May 18:113210. doi: 10.1016/j.yexcr.2022.113210.
    PubMed     Abstract available


  34. CHEN L, Han S, Li Y, Zheng Y, et al
    SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer.
    Exp Cell Res. 2022 May 3:113194. doi: 10.1016/j.yexcr.2022.113194.
    PubMed     Abstract available


    April 2022
  35. SHARMA M, Tollefsbol TO
    Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition.
    Exp Cell Res. 2022 Apr 18:113160. doi: 10.1016/j.yexcr.2022.113160.
    PubMed     Abstract available


  36. ZHU Q, Wan NB, Deng HW, Lu LL, et al
    SEC14L3 plays a tumor-suppressive role in breast cancer through a Wnt/beta-catenin-related way.
    Exp Cell Res. 2022 Apr 18:113161. doi: 10.1016/j.yexcr.2022.113161.
    PubMed     Abstract available


  37. LI L, Gan YP, Peng H
    RAMP2-AS1 inhibits CXCL11 expression to suppress malignant phenotype of breast cancer by recruiting DNMT1 and DNMT3B.
    Exp Cell Res. 2022 Apr 4:113139. doi: 10.1016/j.yexcr.2022.113139.
    PubMed     Abstract available


    March 2022
  38. CHI F, Chen L, Jin X, He G, et al
    CKAP2L, transcriptionally inhibited by FOXP3, promotes breast carcinogenesis through the AKT/mTOR pathway.
    Exp Cell Res. 2022;412:113035.
    PubMed     Abstract available


    February 2022
  39. JOO HJ, Chung GE, Han S, Ka HI, et al
    Adapted suspension tumor cells rewire metabolic pathways for anchorage-independent survival through AKT activation.
    Exp Cell Res. 2022;411:113005.
    PubMed     Abstract available


  40. DEHDARI H, Moradian F, Barzegar A, Ebrahimzadeh MA, et al
    CYP1A1 contiguous hypermethylation within a putative CpG block is associated with breast cancer progression: Feasibility to define boundary motives.
    Exp Cell Res. 2022;413:113062.
    PubMed     Abstract available


  41. MU H, Wang N, Zhao L, Li S, et al
    Corrigendum to "Methylation of PLCD1 and adenovirus-mediated PLCD1 overexpression elicits a gene therapy effect on human breast cancer" [Exp Cell Res. 2015 Mar 15; 332(2):179-89].
    Exp Cell Res. 2022;413:113047.
    PubMed    


    January 2022
  42. HAN X, Long Y, Duan X, Liu Z, et al
    ZEB1 induces ROS generation through directly promoting MCT4 transcription to facilitate breast cancer.
    Exp Cell Res. 2022 Jan 27:113044. doi: 10.1016/j.yexcr.2022.113044.
    PubMed     Abstract available


  43. CHEUNG BCH, Hodgson L, Segall JE, Wu M, et al
    Spatial and temporal dynamics of RhoA activities of single breast tumor cells in a 3D environment revealed by a machine learning-assisted FRET technique.
    Exp Cell Res. 2022;410:112939.
    PubMed     Abstract available


    December 2021
  44. TAKATANI-NAKASE T, Matsui C, Hosotani M, Omura M, et al
    Hypoxia enhances motility and EMT through the Na(+)/H(+) exchanger NHE-1 in MDA-MB-231 breast cancer cells.
    Exp Cell Res. 2021 Dec 31:113006. doi: 10.1016/j.yexcr.2021.113006.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.